Overall CVD disease burden in DALYs attributable to 1^st-level risk factors in Chile. DALYs rates are expressed per 100,000 individuals, with a 95% uncertainty interval. by Camilo Briones-Valdivieso (21567535)

SEM images of alkali-activated samples JW1 and JW3 at a magnification of ×1000. by Liang Li (46069)

SEM images of alkali-activated samples JW1 and JW3 at a magnification of ×1000. by Liang Li (46069)

Dose-response curve of the activity of chitosan solution (A), blank chitosan-TPP nanoparticles (B), AmB loaded chitosan-TPP nanoparticles (C) and AmB solution (pure) (D) against L. by Alaa Riezk (7037297)

Development and Use of a Galectin-1-Specific Nanobody for Tumor Imaging and Elucidating the Role of Galectin‑1 in Cancer by Philippine Granger Joly de Boissel (21688159)

“…Galectin-1 (GAL-1) plays a crucial role in cancer biology, especially in triple-negative breast cancer (TNBC), where it facilitates immune evasion and tumor progression. …”

Data Sheet 1_Lack of association between genetic variations in CYP3A5 and blood pressure or hypertension risk in the UK biobank.pdf by Pia Leibold (21390134)

“…While some previous studies reported that CYP3A5 variants were associated with decreased blood pressure and risk of HTN, others reported no associations. …”

Stress-strain curves under unconfined compression for samples with different cementation concentrations: (a) Concentration of 0.25 mol/L; (b) Concentration of 1 mol/L; (c) Concentr... by Xiaoyan Ding (291429)

Distribution of the unconfined compressive strength of specimens at different positions under different filling speeds: (a) Working condition M1; (b) Working condition M2; (c) Work... by Xiaoyan Ding (291429)

<b>Data for s</b><b>easonal variations in coral lipids and their significance for energy maintenance in the </b><b>South China Sea</b> by Hongyan Mo (19721569)

“…The decrease of ZD is usually accompanied by a reduction in the photosynthetic intensity of the zooxanthellae. …”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of best-corrected visual acuity (BCVA) in all eyes. by Yasuyuki Sotani (20114144)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, the respective treatment counts for anti-VEGF, STTA, MA-PC, PPV, and total treatments (mean ± standard deviation) in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…Outpatient visit frequency also significantly declined from 11.5 ± 4.3 visits in the year before surgery to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal-Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g004" target="_blank">Fig 4</a>).…”

Time course of best-corrected visual acuity (BCVA) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…CRT in the recurrence group significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Regarding the mean number of treatments in the recurrence group, anti-VEGF, STTA, MA-PC, PPV, and total treatment counts in the year before surgery were 3.0 ± 1.4, 0.1 ± 0.3, 0.8 ± 1.0, 0.1 ± 0.3, and 4.0 ± 2.1, respectively. These values significantly decreased in the first postoperative year to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0, and 3.1 ± 2.8; in the second year to 2.1 ± 2.8, 0.4 ± 1.0, 0.0, 0.1 ± 0.3, and 2.6 ± 2.8; and in the third year to 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 (Kruskal–Wallis test, p < 0.001; <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0332941#pone.0332941.g007" target="_blank">Fig 7</a>). …”

Conceptual diagram of survival curve and loss of life expectancy. by Hiroaki Saito (24514)

A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

“…Additionally, it showed effective self-transport capabilities in the transport experiment with a blood droplet, achieving a transport distance of 25 mm and an average speed of 14.2 mm/s. …”

A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

“…Additionally, it showed effective self-transport capabilities in the transport experiment with a blood droplet, achieving a transport distance of 25 mm and an average speed of 14.2 mm/s. …”